After Ups and Downs, Industry Attempts To Normalize In Q3
As Indian Pharma Market Continues To Defy International Trends
Executive Summary
After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.
You may also be interested in...
Nichi-Iko’s Operating Profit Slumps More Than 85% As Price Revisions Bite
Japan’s Nichi-Iko saw its bottom line take a hammering in the six months to 30 September, as a number of its products had their prices cut following revisions to the National Health Insurance program.
Nippon Chemiphar Struggles Despite New Launches
Nippon Chemiphar saw its overall sales drop by 7.9%, dragged down by a fall in generics sales of 9.7%, in its financial first half ended 30 September 2020. The Japanese company’s plan to ride on the success of new launches faltered as it was unable to compensate for the impact of NHI drug price revisions implemented in October 2019 and again in April 2020.
Sawai Draws On Its Strengths Despite Japanese Pressures
In the face of both local and global pressures, Japan’s Sawai Pharmaceutical is holding steady by relying on its core strengths, company president Kenzo Sawai tells Generics Bulletin in the first part of an exclusive two-part interview.